Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Trial Identifier: NT-112-301
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: August 2027
Study Completion Date: April 2044
Condition: Colorectal Cancer; Endometriosis; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90095
US, CA Newport Beach, CA, US, 92663
US, FL Jacksonville, FL, US, 32224
US, IL Chicago, IL, US, 60637
US, KS Westwood, KS, US, 66205
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10016
US, PA Philadelphia, PA, US, 19107
US, PA Pittsburgh, PA, US, 15237
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75246
US, TX Galveston, TX, US, 77555
US, TX Houston, TX, US, 77030
US, WA Aberdeen, WA, US, 98520
US, WI Milwaukee, WI, US, 53226